Abstract
Preterm labour (PTL) can be described as an inflammatory event. C-reactive protein (CRP) and Interleukin-6 (IL-6) are key members of the innate immune response that play major roles in inflammation. The main objective of this case-control study was to determine the association of specific CRP and IL-6 polymorphisms with PTL. The study was carried out in a total of 31 Japanese women with PTL and 28 control women with normal pregnancy. Four SNPs in the CRP gene (rs1800947, rs3091244, rs2794521, and rs3093059) and two SNPs in the IL-6 gene (rs2097677 and rs1800795) were genotyped using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. Biochemical parameters were assayed and cervical length measurements were performed with ultrasound sonography. There were no significant differences in inflammatory markers, including white blood cell count, CRP, neutrophil elastase in cervical mucous, and foetal fibronectin in vaginal discharge, between the PTL and control groups. The frequency of rs1800947 minor allele (G) was significantly higher in the PTL group than in the control group. This finding has not been previously reported. We suggest that mutations in rs1800947 may lead to PTL. Thus, the rs1800947 SNP may be useful as a genetic marker for PTL risk assessment in pregnant women.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by JSPS KAKENHI Grant Number JP 50361225. A.S. of authors received this fund. Funder website is https://www.jsps.go.jp/j-grantsinaid/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the institutional ethics committee of Akita University of Medicine (Approval number: 1431).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are fully available without restriction.
